PMID: 9553675Apr 29, 1998Paper

Leukotriene receptor antagonists and bronchial asthma

Arzneimittel-Forschung
L Jäger, C Kroegel

Abstract

Leukotrienes play an important role in the pathogenesis of the allergic bronchial asthma. The cysteinyl-leukotrienes C4, D4 and E4 (formerly known as slow reacting substance of anaphylaxis, SRS-A) are able to induce all components of the asthmatic reaction. The synthesis of adequate receptor antagonists stimulated expectations to develop on this way new and especially effective antiasthmatic drugs. The results of the first generation was disappointing. Newer compounds are able to protect from bronchoconstriction-inducing noxes (especially in analgesic intolerance), to improve chronic asthma (symptoms scores, long-time resp. rescue medication). Especially remarkable are recent data which prove antiinflammatory activities. Studies are underway to define the position of these drugs in generally accepted recommendations on asthma therapy. This group of drugs is the first one with a defined action.

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

Pharmaceutisch Weekblad. Scientific Edition
F P Nijkamp, J M Sitsen
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
S TeraoY Ashida
Revue des maladies respiratoires
A G Leitch
© 2022 Meta ULC. All rights reserved